NAD · dosing
NAD dosage: which numbers came from trials and which came from clinics
The best-studied oral NAD dosage is 250 mg daily for 12 weeks, from a randomized safety trial. Injectable charts of 20 mg to 100 mg one to three times weekly, by contrast, come from clinic protocols and were never tested against an outcome over weeks or years.
Where do the NAD dose numbers come from?
The dosage figures in circulation come from two places: trials lasting 10 to 12 weeks (per Okabe 2022), and clinic charts. Oral precursor doses come from randomized trials that measured blood NAD and, occasionally, a functional endpoint. Injectable doses come from standard operating procedures written by clinics and compounding pharmacies.
Both appear in the same search results, formatted identically as charts. Only one kind has a study behind it, and the difference is invisible unless someone tells you.
Which oral NAD dosage numbers came from trials?
Early / mixed evidence A dose-ranging randomized, multicenter, double-blind trial in healthy middle-aged adults found blood NAD rising with dose and reported oral dosing safe and well tolerated up to 900 mg daily.[1] A separate trial gave 250 mg daily for twelve weeks, split as 125 mg twice daily, with the same result.[2]
Show the numbers as a table
| Measure | Value |
|---|---|
| Okabe 2022, 12-week trial | 250 mg/day |
| Yi 2023, top tested dose | 900 mg/day |
Those are genuine dose data. What they establish is that the compound is tolerable at those amounts and that it raises the marker it is supposed to raise. Neither trial identified a dose that produced a benefit, because that was not what either was designed to find.
The nicotinamide riboside trial doses
Nicotinamide riboside has a separate record. A randomized, placebo-controlled trial used 1,000 mg daily for six weeks in healthy middle-aged and older adults and found it well tolerated while raising NAD.[8]
That trial is useful for what it did not find as much as for what it did. It reported no clear functional outcome, so its dose is another tolerability and marker figure rather than a dose shown to help.
Trial doses side by side
| Compound and trial | Daily oral dose | Duration | What it showed |
|---|---|---|---|
| NMN, Okabe 2022 | 250 mg | 12 weeks | Safe, blood NAD up |
| NMN, Yoshino 2021 | 250 mg | 10 weeks | Muscle insulin sensitivity up |
| NMN, Yi 2023 | Up to 900 mg | Dose-ranging | Tolerated, NAD rose with dose |
| NR, Martens 2018 | 1,000 mg | 6 weeks | Tolerated, NAD up |
The one oral dose tied to a measured change
A ten-week trial in prediabetic postmenopausal women gave 250 mg of NMN daily and found improved insulin sensitivity in muscle.[9] It is the most cited positive result, and it used the same modest amount as the Japanese safety trial rather than the higher figures sold as premium.
Where do injectable NAD doses come from?
They come from clinic and compounding pharmacy protocols, not from trials. Live search results for this term are dominated by compounding pharmacies and infusion clinics publishing dosing charts. The figures cluster consistently: subcutaneous protocols starting around 20 mg and titrating toward 100 mg, injections one to three times weekly, with intravenous sessions running to several hundred milligrams over several hours.
Read those as what they are. A standard operating procedure describes how a provider administers a product, and it differs from a trial in three ways:
- It is not a dose-finding study.
- It has no control group.
- The outcome it was optimized against is tolerability rather than benefit.
The consistency between clinics reflects a shared commercial template more than a shared evidence base.
Per day, per week and per vial
Injectable charts switch between milligrams, milliliters and syringe units, and the conversion depends entirely on the concentration of the compounded vial. Two clinics quoting the same volume can be delivering different amounts of NAD.
That is another sign the numbers are operating instructions for one product, not transferable doses. Asking for the milligram amount and the vial concentration is the only way to compare one chart with another, and a provider unable to state both is not working from a dose at all.
Can oral and injectable milligrams be compared?
No, because the two routes deliver different molecules. NAD+ itself is a large molecule, and most oral products supply precursors such as NMN or nicotinamide riboside instead of NAD.[6]
An injection delivers NAD directly into tissue or blood, while a capsule delivers a precursor that the body converts. A milligram of one is not a milligram of the other, so a 100 mg injection and a 250 mg capsule cannot be ranked on a single scale.
| Route | What is delivered | Where the dose figures come from |
|---|---|---|
| Oral capsule or powder | A precursor such as NMN or NR | Randomized trials |
| Subcutaneous or intramuscular | Compounded NAD | Clinic and pharmacy protocols |
| Intravenous drip | Compounded NAD | Clinic protocols, paced by symptoms |
Why do NAD infusions take so long?
Because speed causes the symptoms. Flushing, chest pressure, nausea and cramping during a drip are widely described, and the standard remedy is to slow the rate. A session stretched over several hours is a tolerability management strategy, and it explains the price as much as the pharmacology does.
Our page on the side effect profile by route goes through that difference in full, including the regulatory position on compounded injectables.
Does a higher dose bring more benefit?
Not on current evidence: no dose by any route has been tied to a functional gain. In a 21-day placebo-controlled crossover trial, 12 men aged 70 to 80 took 1,000 mg of nicotinamide riboside daily: muscle NAD metabolites rose, while muscle strength and mitochondrial measures did not improve.[3]
Twelve men over three weeks cannot rule out a slower effect. If raising the marker does not reliably move the outcome, then the dose that raises the marker most is not obviously the dose worth taking. Optimizing a number whose relationship to benefit is unproven is an expensive way to be precise about nothing.
What sets the upper limit on dose?
The older B3 compounds in many blends set it, not NMN or NR: for nicotinamide, adverse effects including headache, dizziness and vomiting have been documented in healthy people at multi-gram doses, alongside mechanistic questions about the methyl donors its metabolism consumes.[4] Reviews of NAD-boosting strategies raise related concerns about high-dose niacin, blood sugar and homocysteine.[5]
So the practical ceiling is not set by NMN or NR, whose reported tolerability is good, but by the older B3 compounds sitting alongside them in many formulations. Checking the label matters more than choosing between 250 mg and 500 mg of the headline ingredient.
Does body weight change the dose?
Not in any trial this page cites. Every one used a fixed milligram amount for all participants, whether 250 mg or 1,000 mg daily, rather than a dose per kilogram.[2] [8]
Weight-based figures on clinic charts are therefore another protocol convention. They may be sensible for managing infusion tolerability, but no study has shown that scaling the amount to body size changes what it does. A chart that adjusts by weight is borrowing the look of precision.
Should the daily dose be split?
No study has shown that splitting changes the result. Two trials split their daily amount: 125 mg of NMN twice daily in one, and 500 mg of nicotinamide riboside twice daily in the other.[2] [8] Neither compared a split schedule with a single dose, so the choice reflects trial design rather than a tested advantage.
Splitting is a reasonable way to smooth stomach upset, and it is how the trial participants took their doses. It is not evidence that a divided amount raises NAD more or does more than the same total taken at once.
How long before a dose does anything?
Blood NAD moves within the length of a trial, and function mostly did not move at all. The oral trials confirmed higher blood levels at their end points, and the dose-ranging trial found the rise grew with the amount taken.[1]
Anything beyond the marker is slower and less certain. The functional trials ran six to twelve weeks and mostly found nothing, so a claim of feeling a difference within days describes expectation more than measured effect. None of the trials asked participants to judge a dose by how they felt.
Has any regulator approved an NAD dose?
No agency has approved a dose of any of these compounds for aging or energy. For NMN, the regulatory position itself moved, and the reversal is instructive.
| Date | FDA position on NMN | Does it set a dose? |
|---|---|---|
| November 2022 | Excluded from the dietary supplement definition | No |
| September 2025 | Not drug-precluded, lawful in supplements | No |
In September 2025 the FDA reversed its 2022 view that NMN was excluded from the supplement definition and concluded it is lawful in supplements.[10] Legal to sell is not the same as a validated dose. The amount printed on a label is a manufacturer choice, not a regulator decision.
What should be watched while taking a precursor?
There is no established monitoring panel, because there is no approved indication to monitor against. The documented concerns point to what is worth raising with a clinician instead.
- Blood sugar: relevant for anyone on diabetes medication, since high-dose niacin is associated with raised glucose.
- Homocysteine: named in reviews of high-dose niacin and nicotinamide metabolism.
- Infusion details: what is being infused, at what rate, and which pharmacy compounded it.
- The label: whether niacin or nicotinamide is present, and in what amount.
Those points come from the same reviews that set the practical dose ceiling.[5]
How can you judge any NAD dosage chart?
Judge it by three questions about its author, its route and its target:
- Who published it, and do they sell the thing it describes?
- Which route is it for, since oral and injectable are not comparable?
- What was the number optimized against, an outcome or the absence of complaints?
The three questions applied
Neither column reaches an outcome. The oral figure at least has a control group and a published safety record behind it, which is the most any number on this page can claim.[2]
| Question | Oral trial dose (250 mg NMN) | Injectable chart (20 mg to 100 mg) |
|---|---|---|
| Who published it? | University and hospital researchers in a peer-reviewed journal | A clinic or compounding pharmacy that sells the product |
| Which route? | A precursor swallowed and converted by the body | Compounded NAD injected under the skin |
| Optimized against what? | Safety panels and blood NAD over twelve weeks | Tolerability during administration |
| What it cannot tell you | Whether that dose improves health | Whether any dose improves health |
Institutional summaries remain more measured than the commercial ones, describing the supplements as generally well tolerated while noting how limited the evidence is.[6] Coverage of the wider NAD boom has made the same point about how far the market has run ahead of the data.[7]
Our pages on what NAD does, the NMN dose evidence and the booster category cover the rest.
Show the numbers as a table
| When | Event | Detail |
|---|---|---|
| 2019 | Muscle NAD study | Marker up, function flat |
| 2020 | Nicotinamide review | Multi-gram adverse effects |
| 2022 | 12-week oral trial | 125 mg twice daily |
| 2023 | Dose-ranging trial | Tolerated up to 900 mg |
| 2026 | NAD boom coverage | Market ahead of data |
None of those dates marks a trial that tied a dose to a lasting health outcome, which is why every chart, oral or injectable, should be read as a starting point for questions rather than as an instruction.
Frequently asked questions
What is the correct NAD dosage?
There is no approved dosage for any route. Oral precursors have been studied at 250 mg to 1,200 mg daily. Injectable protocols in circulation typically run 20 mg to 100 mg subcutaneously one to three times weekly, and those figures come from clinic and compounding pharmacy protocols rather than from trials.
How long has any oral NAD precursor dose been studied?
The longest trial cited here ran twelve weeks, at 250 mg daily. No study has followed a dose over years, so every chart that implies indefinite daily use is extrapolating well beyond the data behind it.
What is the starting dose for NAD injections?
Published clinic protocols commonly start around 20 mg subcutaneously and titrate upward toward 100 mg. Those are operating procedures written by the clinics and pharmacies providing the service, not doses established by any randomized study.
Why can two injection charts quoting the same volume differ?
Because a milliliter or syringe unit means nothing without the concentration of the compounded vial. Two clinics can quote the same volume while delivering different milligram amounts, so the mg figure and the vial strength are the numbers to ask for.
How often should NAD injections be given?
Circulating protocols range from one to three times weekly, with loading schedules and maintenance schedules that differ by provider. The variation between providers is itself informative: there is no standard because nothing has been standardized against an outcome.
Why do IV NAD infusions take hours?
Because infusing quickly produces flushing, chest tightness, nausea and cramping. Slowing the drip resolves them. The multi-hour session length is a tolerability management decision rather than a pharmacological requirement.
Is oral or injectable NAD dosing better?
Neither has demonstrated a functional benefit, so the comparison has no outcome to settle it on. Oral precursors have actual randomized trials behind their doses. Injectables have clinic protocols and a much higher price.
Does NAD dosage depend on body weight?
No human dosing study has established weight-based dosing for any route. Trials used fixed oral doses. Weight-based charts appear online and are extrapolated rather than measured.
What is the maximum safe NAD dose?
No upper limit has been established for any route. Oral trials found tolerability up to 900 mg daily over weeks. For nicotinamide specifically, adverse effects including headache, dizziness and vomiting have been documented at multi-gram doses.
Did any trial compare one daily dose with a split dose?
One safety trial used 125 mg twice daily rather than a single 250 mg dose, and no study has compared the two schedules. Splitting is a reasonable habit rather than an evidence-based instruction.
How long before an NAD dose does anything?
Blood NAD precursor levels rise within one to two weeks of oral dosing. Functional changes, in the small number of trials reporting any, took eight to twelve weeks. Anything felt during an infusion is not the coenzyme working.
Do higher doses raise NAD more?
Yes, dose-dependently, which the dose-ranging trial demonstrated clearly. The unresolved problem is that a trial raising NAD in human muscle found no improvement in muscle function, so raising the marker further is not obviously worth paying for.
What monitoring goes with NAD dosing?
Nothing is formally required, since none of this is an approved therapy. If you are on medication for diabetes, glucose is worth watching given the effects reported across this compound family in both directions.
How much NAD should I take, if any?
If taking an oral precursor, staying inside the studied range and starting at the low end is the defensible position. If considering an infusion, the questions worth asking are what is being infused, compounded by whom, at what rate, and on what evidence the protocol was written.
References
10 sources, all link-checked; oldest check
- The efficacy and safety of beta-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial. Yi L et al. GeroScience 2023 (cited 260).Dose-ranging trial; blood NAD rose with dose and oral dosing up to 900 mg daily was safe and well tolerated.Verified Sep 15, 2026
- Oral administration of nicotinamide mononucleotide is safe and efficiently increases blood nicotinamide adenine dinucleotide levels in healthy subjects. Okabe K et al. Frontiers in Nutrition 2022 (cited 134).250 mg daily for 12 weeks in healthy adults was safe and well tolerated and raised blood NAD.Verified Sep 15, 2026
- Nicotinamide riboside augments the aged human skeletal muscle NAD+ metabolome and induces transcriptomic and anti-inflammatory signatures. Elhassan YS et al. Cell Reports 2019;28(7):1717–1728.e6.Raised muscle NAD+ metabolites without a matching change in functional performance.Verified Sep 15, 2026
- NAD+ supplements: can they really slow down aging?. Cleveland Clinic Health Essentials, 26 February 2026.Mainstream clinical overview; notes NAD+ itself is a large molecule and that most products supply precursors instead.Verified Sep 15, 2026
- Possible adverse effects of high-dose nicotinamide: mechanisms and safety assessment. Hwang ES, Song SB. Biomolecules 2020 (cited 167).Headache, dizziness and vomiting reported in healthy people at nicotinamide doses up to 6 g; reviews methyl-donor depletion and other high-dose mechanisms.Verified Sep 15, 2026
- Current uncertainties and future challenges regarding NAD+ boosting strategies. Poljsak B et al. Antioxidants 2022 (cited 50).Notes hot flushes and raised blood sugar and homocysteine with high-dose niacin, and unresolved questions about sustained NAD elevation.Verified Sep 15, 2026
- Celebrities and influencers tout NAD+. But is the science there?. The New York Times, 23 May 2026.Mainstream press assessment of the NAD+ supplement category and its evidence base.Publisher blocks automated checks · last tried Sep 15, 2026
- Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. Martens CR et al. Nature Communications 2018;9:1286.Randomized, placebo-controlled; raised NAD+, no clear functional outcome.Verified Sep 15, 2026
- Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Yoshino M et al. Science 2021;372(6547):1224–1229.Publisher blocks automated checks · last tried Sep 15, 2026
- FDA response to citizen petition on beta-nicotinamide mononucleotide (NMN). US Food and Drug Administration, letter of 29 September 2025, docket FDA-2023-P-0872.Reversal of the 2022 position: FDA concluded NMN is not drug-precluded and is not excluded from the dietary supplement definition.Verified Sep 15, 2026
Every link above is re-requested on a schedule by an automated checker; the date shown is when it last answered. Publishers that block automated requests are marked as such rather than reported broken. Our editorial standards explain how a source gets cited here in the first place.
Filed by the Rapamycin.store evidence desk. Each source is re-checked when the page is reviewed.
Own a longevity or health brand?
Rapamycin.store publishes sponsored and guest posts on an aged, topically-relevant domain, and offers display advertising. Tell us what you want to promote and we'll send our current options.